Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RPHM

Reneo Pharmaceuticals (RPHM) Stock Price, News & Analysis

Reneo Pharmaceuticals logo

About Reneo Pharmaceuticals Stock (NASDAQ:RPHM)

Advanced Chart

Key Stats

Today's Range
$1.68
$1.90
50-Day Range
$1.31
$1.82
52-Week Range
$0.98
$9.21
Volume
437,523 shs
Average Volume
250,384 shs
Market Capitalization
$60.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Receive RPHM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RPHM Stock News Headlines

Onkure Therapeutics Inc (OKUR)
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
See More Headlines

RPHM Stock Analysis - Frequently Asked Questions

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) issued its quarterly earnings results on Monday, March, 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.03.

Reneo Pharmaceuticals (RPHM) raised $101 million in an initial public offering (IPO) on Friday, April 9th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Reneo Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Invesco QQQ (QQQ), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
3/27/2023
Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RPHM
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$77.39 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.66 per share
Price / Book
0.68

Miscellaneous

Free Float
27,439,000
Market Cap
$60.84 million
Optionable
Optionable
Beta
0.21
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:RPHM) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners